Literature DB >> 33833435

Registration trials in countries without access to US standards of care - pitfalls of interpretation.

Garth W Strohbehn1,2, Daniel A Goldstein3,4,5.   

Abstract

Year:  2021        PMID: 33833435     DOI: 10.1038/s41571-021-00506-z

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Thomas Powles; Mauricio Burotto; Bernard Escudier; Maria T Bourlon; Bogdan Zurawski; Victor M Oyervides Juárez; James J Hsieh; Umberto Basso; Amishi Y Shah; Cristina Suárez; Alketa Hamzaj; Jeffrey C Goh; Carlos Barrios; Martin Richardet; Camillo Porta; Rubén Kowalyszyn; Juan P Feregrino; Jakub Żołnierek; David Pook; Elizabeth R Kessler; Yoshihiko Tomita; Ryuichi Mizuno; Jens Bedke; Joshua Zhang; Matthew A Maurer; Burcin Simsek; Flavia Ejzykowicz; Gisela M Schwab; Andrea B Apolo; Robert J Motzer
Journal:  N Engl J Med       Date:  2021-03-04       Impact factor: 91.245

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.